ENTERA BIO LTD. Cash and Restricted Cash
ENTERA BIO LTD. (ENTX) had Cash and Restricted Cash of $18.53 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.53M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.02M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.97M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.69M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $18.53M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $12.02M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $14.97M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $16.69M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $18.95M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $20.66M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $8.74M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $6.99M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $9.13M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $9.25M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $11.09M 10-K · filed 2026-03-27 |
| 2023-09-30 | $7.68M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $9.20M 10-Q · filed 2024-08-09 |
| 2023-03-31 | $10.76M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $12.38M 10-K · filed 2025-03-28 |
| 2022-09-30 | $14.39M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $17.32M 10-Q · filed 2023-08-11 |
| 2022-03-31 | $20.15M 10-Q · filed 2023-05-05 |
| 2021-12-31 | $24.96M 10-K · filed 2024-03-08 |
| 2021-09-30 | $27.46M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $27.00M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $16.45M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $8.66M 10-K · filed 2023-03-31 |
| 2019-12-31 | $15.22M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |